Mitochondrial dysfunctions are supposed to be responsible for many neurodegenerative diseases dominating in Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). A growing body of evidence suggests that defects in mitochondrial metabolism and particularly of electron transport chain may play a role in pathogenesis of AD. Structurally and functionally damaged mitochondria do not produce sufficient ATP and are more prominent in producing proapoptotic factors and reactive oxygen species (ROS), and this can be an early stage of several mitochondrial disorders, including neurodegenerative diseases. Mitochondrial dysfunctions may be caused by both mutations in mitochondrial or nuclear DNA that code mitochondrial components and by environmental causes. In the following review, common aspects of mitochondrial impairment concerned about neurodegenerative diseases are summarized including ROS production, impaired mitochondrial dynamics, and apoptosis. Also, damaged function of electron transport chain complexes and interactions between pathological proteins and mitochondria are described for AD particularly and marginally for PD and HD.

Department of Psychiatry 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Ke Karlovu 11 120 00 Prague 2 Czech Republic

Zobrazit více v PubMed

Eckert A, Keil U, Marques CA, et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease. Biochemical Pharmacology. 2003;66(8):1627–1634. PubMed

Hsieh HL, Yang CM. Role of redox signaling in neuroinflammation and neurodegenerative diseases. BioMed Research International. 2013;2013:18 pages.484613 PubMed PMC

Anandatheerthavarada HK, Devi L. Amyloid precursor protein and mitochondrial dysfunction in Alzheimer’s disease. Neuroscientist. 2007;13(6):626–638. PubMed

Moreira PI, Santos MS, Oliveira CR. Alzheimer’s disease: a lesson from mitochondrial dysfunction. Antioxidants and Redox Signaling. 2007;9(10):1621–1630. PubMed

Orth M, Schapira AHV. Mitochondria and degenerative disorders. American Journal of Medical Genetics—Seminars in Medical Genetics. 2001;106(1):27–36. PubMed

Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–795. PubMed

Sas K, Robotka H, Toldi J, Vécsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. Journal of the Neurological Sciences. 2007;257(1-2):221–239. PubMed

Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomedicine and Pharmacotherapy. 2004;58(1):39–46. PubMed

Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. Journal of Neurochemistry. 1990;54(3):823–827. PubMed

Parker WD, Jr., Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Annals of Neurology. 1989;26(6):719–723. PubMed

Moran M, Moreno-Lastres D, Marin-Buera L, Arenas J, Martin MA, Ugalde C. Mitochondrial respiratory chain dysfunction: implications in neurodegeneration. Free Radical Biology & Medicine. 2012;53:595–609. PubMed

Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M. Mitochondria and neurodegeneration. Bioscience Reports. 2007;27(1–3):87–104. PubMed

Garcia-Escudero V, Martin-Maestro P, Perry G, Avila J. Deconstructing mitochondrial dysfunction in Alzheimer disease. Oxidative Medicine and Cellular Longevity. 2013;2013:13 pages.162152 PubMed PMC

Cho D, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cellular and Molecular Life Sciences. 2010;67(20):3435–3447. PubMed PMC

Hall AR, Burke N, Dongworth RK, Hausenloy DJ. Mitochondrial fusion and fission proteins: novel therapeutic targets for combating cardiovascular disease. British Journal of Pharmacology. 2014;171:1890–1906. PubMed PMC

Su B, Wang X, Bonda D, Perry G, Smith M, Zhu X. Abnormal mitochondrial dynamics—a novel therapeutic target for alzheimer’s disease? Molecular Neurobiology. 2010;41(2-3):87–96. PubMed PMC

Wang X, Su B, Siedlak SL, et al. Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(49):19318–19323. PubMed PMC

Wang X, Su B, Lee H, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. The Journal of Neuroscience. 2009;29(28):9090–9103. PubMed PMC

Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Human Molecular Genetics. 2011;20(23):4515–4529.ddr381 PubMed PMC

Wang X, Su B, Fujioka H, Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. American Journal of Pathology. 2008;173(2):470–482. PubMed PMC

Schulz KL, Eckert A, Rhein V, et al. A new link to mitochondrial impairment in tauopathies. Molecular Neurobiology. 2012;46:205–216. PubMed

Chaturvedi RK, Flint Beal M. Mitochondrial diseases of the brain. Free Radical Biology and Medicine. 2013;63:1–29. PubMed

Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. The Journal of Biological Chemistry. 2005;280(28):26185–26192. PubMed

Olichon A, Guillou E, Delettre C, et al. Mitochondrial dynamics and disease, OPA1. Biochimica et Biophysica Acta—Molecular Cell Research. 2006;1763(5-6):500–509. PubMed

Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Human Molecular Genetics. 2011;20(13):2495–2509. PubMed PMC

Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Human Molecular Genetics. 2012;21:5131–5146. PubMed PMC

Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology. 2006;66:S74–S78. PubMed

Meredith SC. Protein denaturation and aggregation: cellular responses to denatured and aggregated proteins. Annals of the New York Academy of Sciences. 2005;1066:181–221. PubMed

Valincius G, Heinrich F, Budvytyte R, et al. Soluble amyloid β-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. Biophysical Journal. 2008;95(10):4845–4861. PubMed PMC

Reddy PH, Shirendeb UP. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. Biochimica et Biophysica Acta—Molecular Basis of Disease. 2012;1822(2):101–110. PubMed PMC

Bossy-Wetzel E, Petrilli A, Knott AB. Mutant huntingtin and mitochondrial dysfunction. Trends in Neurosciences. 2008;31(12):609–616. PubMed PMC

Kim J, Moody JP, Edgerly CK, et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Human Molecular Genetics. 2010;19(20):3919–3935. PubMed PMC

Choi P, Golts N, Snyder H, et al. Co-association of parkin and α-synuclein. NeuroReport. 2001;12(13):2839–2843. PubMed

Yasuda T, Mochizuki H. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson’s disease. Apoptosis. 2010;15(11):1312–1321. PubMed

Yang Y, Ouyang Y, Yang L, et al. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(19):7070–7075. PubMed PMC

Deng H, Dodson MW, Huang H, Guo M. The Parkinson’s disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(38):14503–14508. PubMed PMC

Whitworth AJ, Pallanck LJ. The PINK1/Parkin pathway: a mitochondrial quality control system? Journal of Bioenergetics and Biomembranes. 2009;41(6):499–503. PubMed

Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 2001;40(8):959–975. PubMed

Rhein V, Baysang G, Rao S, et al. Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cellular and Molecular Neurobiology. 2009;29(6-7):1063–1071. PubMed PMC

van den Heuvel LP, Smeitink JA, Rodenburg RJT. Biochemical examination of fibroblasts in the diagnosis and research of oxidative phosphorylation (OXPHOS) defects. Mitochondrion. 2004;4(5-6):395–401. PubMed

Murphy MP. How mitochondria produce reactive oxygen species. Biochemical Journal. 2009;417(1):1–13. PubMed PMC

Hroudová J, Fišar Z. Control mechanisms in mitochondrial oxidative phosphorylation. Neural Regeneration Research. 2013;8(4):363–375. PubMed PMC

Starkov AA. The role of mitochondria in reactive oxygen species metabolism and signaling. Annals of the New York Academy of Sciences. 2008;1147:37–52. PubMed PMC

Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012;20:127–150. PubMed

Schönfeld P, Wojtczak L. Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radical Biology and Medicine. 2008;45(3):231–241. PubMed

Boffoli D, Scacco SC, Vergari R, Solarino G, Santacroce G, Papa S. Decline with age of the respiratory chain activity in human skeletal muscle. Biochimica et Biophysica Acta—Molecular Basis of Disease. 1994;1226(1):73–82. PubMed

Brieger K, Schiavone S, Miller FJ, Jr., Krause KH. Reactive oxygen species: from health to disease. Swiss Medical Weekly. 2012;142w13659 PubMed

Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008;60(5):748–766. PubMed PMC

Aronis A, Melendez JA, Golan O, Shilo S, Dicter N, Tirosh O. Potentiation of Fas-mediated apoptosis by attenuated production of mitochondria-derived reactive oxygen species. Cell Death and Differentiation. 2003;10(3):335–344. PubMed

Lu B. Mitochondrial dynamics and neurodegeneration. Current Neurology and Neuroscience Reports. 2009;9(3):212–219. PubMed PMC

Musatov A, Robinson NC. Susceptibility of mitochondrial electron-transport complexes to oxidative damage. Focus on cytochrome c oxidase. Free Radical Research. 2012;46:1313–1326. PubMed

Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene. 2002;286(1):135–141. PubMed

Paradies G, Paradies V, de Benedictis V, Ruggiero FM, Petrosillo G. Functional role of cardiolipin in mitochondrial bioenergetics. Biochimica et Biophysica Acta. 2014;1837:408–417. PubMed

Yin H, Zhu M. Free radical oxidation of cardiolipin: chemical mechanisms, detection and implication in apoptosis, mitochondrial dysfunction and human diseases. Free Radical Research. 2012;46:959–974. PubMed

Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. NeuroMolecular Medicine. 2003;4(1-2):21–36. PubMed

Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends in Molecular Medicine. 2008;14(2):45–53. PubMed PMC

Onyango I, Khan S, Miller B, Swerdlow R, Trimmer P, Bennett J., Jr. Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer’s disease. Journal of Alzheimer’s Disease. 2006;9(2):183–193. PubMed

Aksenov MY, Tucker HM, Nair P, et al. The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer’s disease. Neurochemical Research. 1999;24(6):767–774. PubMed

Manczak M, Park BS, Jung Y, Reddy PH. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. NeuroMolecular Medicine. 2004;5(2):147–162. PubMed

Chandrasekaran K, Hatanpaa K, Brady DR, Rapoport SI. Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Experimental Neurology. 1996;142:80–88. PubMed

Parker WD, Jr., Parks J, Filley CM, Kleinschmidt-DeMasters BK. Electron transport chain defects in Alzheimer’s disease brain. Neurology. 1994;44(6):1090–1096. PubMed

Fukuyama R, Hatanpaa K, Rapoport SI, Chandrasekaran K. Gene expression of ND4, a subunit of complex I of oxidative phosphorylation in mitochondria, is decreased in temporal cortex of brains of Alzheimer's disease patients. Brain Research. 1996;713:290–293. PubMed

Mancuso M, Calsolaro V, Orsucci D, Siciliano G, Murri L. Is there a primary role of the mitochondrial genome in Alzheimer’s disease? Journal of Bioenergetics and Biomembranes. 2009;41(5):411–416. PubMed

Nagy Z, Esiri MM, LeGris M, Matthews PM. Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathologica. 1999;97(4):346–354. PubMed

Cottrell DA, Borthwick GM, Johnson MA, Ince PG, Turnbull DM. The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer’s disease. Neuropathology and Applied Neurobiology. 2002;28(5):390–396. PubMed

Fukui H, Diaz F, Garcia S, Moraes CT. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(35):14163–14168. PubMed PMC

Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell. 2007;130(3):548–562. PubMed

Parker WD, Jr., Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology. 1990;40(8):1302–1303. PubMed

Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer’s disease. Journal of Neurochemistry. 1994;63(6):2179–2184. PubMed

Maurer I, Zierz S, Möller H. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiology of Aging. 2000;21(3):455–462. PubMed

Valla J, Schneider L, Niedzielko T, et al. Impaired platelet mitochondrial activity in Alzheimer’s disease and mild cognitive impairment. Mitochondrion. 2006;6(6):323–330. PubMed PMC

Candy JM, Perry RH, Perry EK. Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases. Journal of the Neurological Sciences. 1983;59(2):277–289. PubMed

Fodero LR, Mok SS, Losic D, et al. α7-nicotinic acetylcholine receptors mediate an Aβ 1-42-induced increase in the level of acetylcholinesterase in primary cortical neurones. Journal of Neurochemistry. 2004;88(5):1186–1193. PubMed

Feldhaus P, Fraga DB, Ghedim FV, et al. Evaluation of respiratory chain activity in lymphocytes of patients with Alzheimer disease. Metabolic Brain Disease. 2011;26(3):229–236. PubMed

Gibson GE, Starkov A, Blass JP, Ratan RR, Beal MF. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochimica et Biophysica Acta—Molecular Basis of Disease. 2010;1802(1):122–134. PubMed PMC

Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. The American Journal of Physiology—Cell Physiology. 2007;292(2):C670–C686. PubMed

Kilbride SM, Gluchowska SA, Telford JE, O’Sullivan C, Davey GP. High-level inhibition of mitochondrial complexes III and IV is required to increase glutamate release from the nerve terminal. Molecular Neurodegeneration. 2011;6(1, article 53) PubMed PMC

Kilbride SM, Telford JE, Tipton KF, Davey GP. Partial inhibition of complex I activity increases Ca2+-independent glutamate release rates from depolarized synaptosomes. Journal of Neurochemistry. 2008;106(2):826–834. PubMed

Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35(3):730–743. PubMed

Eckert GP, Renner K, Eckert SH, et al. Mitochondrial dysfunction—a pharmacological target in Alzheimer's disease. Molecular Neurobiology. 2012;46:136–150. PubMed

Casademont J, Miró O, Rodriguez-Santiago B, Viedma P, Blesa R, Cardellach F. Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer’s disease. Journal of the Neurological Sciences. 2003;206(1):23–26. PubMed

Rhein V, Song X, Wiesner A, et al. Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(47):20057–20062. PubMed PMC

Bosetti F, Brizzi F, Barogi S, et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer’s disease. Neurobiology of Aging. 2002;23(3):371–376. PubMed

Valla J, Berndt JD, Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer’s patients: superficial laminar cytochrome oxidase associated with disease duration. The Journal of Neuroscience. 2001;21(13):4923–4930. PubMed PMC

Baloyannis SJ, Costa V, Michmizos D. Mitochondrial alterations in Alzheimer’s disease. American Journal of Alzheimer’s Disease and other Dementias. 2004;19(2):89–93. PubMed PMC

Kim SH, Vlkolinsky R, Cairns N, Lubec G. Decreased levels of complex III core protein 1 and complex V β chain in brains from patients with Alzheimer’s disease and down syndrome. Cellular and Molecular Life Sciences. 2000;57(12):1810–1816. PubMed PMC

Kish SJ, Bergeron C, Rajput A, et al. Brain cytochrome oxidase in Alzheimer’s disease. Journal of Neurochemistry. 1992;59(2):776–779. PubMed

Kim SH, Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G. The reduction of NADH—ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer’s disease. Life Sciences. 2001;68(24):2741–2750. PubMed

Gan X, Huang S, Wu L, et al. Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell. Biochimica et Biophysica Acta. 2014;1842:220–231. PubMed PMC

Kushnareva Y, Murphy AN, Andreyev A. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochemical Journal. 2002;368(2):545–553. PubMed PMC

Caspersen C, Wang N, Yao J, et al. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. The FASEB Journal. 2005;19(14):2040–2041. PubMed

Cardoso SM, Proença MT, Santos S, Santana I, Oliveira CR. Cytochrome c oxidase is decreased in Alzheimer’s disease platelets. Neurobiology of Aging. 2004;25(1):105–110. PubMed

Prominent Perspective on Existing Biological Hallmarks of Alzheimer's Disease

CoQ10 and Mitochondrial Dysfunction in Alzheimer's Disease

Age-Dependent Alterations in Platelet Mitochondrial Respiration

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets

Mitochondrially-Targeted Therapeutic Strategies for Alzheimer's Disease